

SEP. 30. 2004 4:44PM

AVENTIS US PAT DEPT

SEP 30 2004 NO. 8197 P. 1

**FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:
HMR2023 US PCT

Applicants:
David M. Fink et al

Serial No.
10/088,250

Filing Date:
December 23, 2002

Title of Invention:
**THIENOISOXAZOLYL-AND THIENYLPYRRAZOLYL-PHENOXY SUBSTITUTED PROPYL
DERIVATIVES USEFUL AS D4 ANTAGONISTS**

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being transmitted via
facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, at 703-872-9306, on
Date of Deposit September 30, 2004
Printed Name of Person Signing Certificate Generia Walker
Signature Generia Walker

Total Number of Pages Sent: **7**

Attorney: **Barbara E. Kurys**

Group Art Unit: **1626**

Examiner: **Wright, Sonya N.**

TO: Mail Stop Art Unit 1626
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet,
signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit
account (18-1982) in the name of **Aventis Pharmaceuticals Inc.**

- | | |
|--|---|
| <input checked="" type="checkbox"/> Amendment, 37 CFR <u>5 PGS.</u> | <input checked="" type="checkbox"/> Fax Transmittal <u>1 PG</u> |
| <input type="checkbox"/> Charge deposit account, in duplicate | <input type="checkbox"/> Petition under 37 CFR _____ |
| <input checked="" type="checkbox"/> Extension of Time Petition <u>1 PG</u> | <input type="checkbox"/> Other _____ |
| <input type="checkbox"/> Issue Fee Transmittal & Advance Order | <input type="checkbox"/> Other _____ |
| <input type="checkbox"/> Maintenance Fee Transmittal | |

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this
telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

SEP. 30. 2004 4:45PM

AVENTIS US PAT DEPT

RECEIVED
CENTRAL INTELLIGENCE

NO. 8197 P. 3

SEP 30 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
David M. Fink et al

Examiner: Wright, Sonya N.

Art Unit: 1626

Application No.: 10/088,250

Filed: December 23, 2002

Title: **THIENOISOXAZOLYL-AND
THIENYPYRAZOLYL-PHENOXY
SUBSTITUTED PROPYL
DERIVATIVES USEFUL AS D4
ANTAGONISTS**

TELEFAX CERTIFICATE

I hereby certify that this correspondence is being
transmitted via facsimile to the Commissioner for
Patents, Alexandria, VA 22313, on

Date of transmission

Signature

RESPONSE TO REQUIREMENT FOR RESTRICTION

Mail Stop Art Unit 1626
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

The Examiner required restriction to one of the following exemplary groups of Claims under PCT
Rule 13.2:

Group I, claims 1-120, 124, and 125, drawn to compounds and compositions of formula I, wherein X
is N(CH₃), R₁ is OH or alkoxy, R₂ is H or C₁-C₆alkyl, R₃ is indanyl, and R₄ is H or C₁-C₆alkyl,
classified in class 548 and subclass 356.1+.

Group II, claim 121, drawn to a compound wherein X is N(CH₃) and R₁ is C₁-C₆alkyl, classified in
class 548 and subclass 356.1+.

Group III, claim 122, drawn to a compound wherein X is O, R₁ is H or C₁-C₆alkyl, and R₂ is CH₃,
F, p-bromobenzene, p-nitrobenzene, or p-methylbenzene, classified in class 548 and subclass 356.1+.

Group IV, claims 123 and 126-136, drawn to methods of use for compound of formula I wherein X
is N(CH₃), R₁ is OH or alkoxy, R₂ is H or C₁-C₆alkyl, R₃ is adamantyl, and R₄ is H or C₁-C₆alkyl,
classified in class 548 and subclass 356.1+.

Group V, claim 137, drawn to a process for the preparation of a compound of the formula I, wherein X is N(CH₃), R₁ is OH or C₁-C₆alkoxy, R₂ is H or C₁-C₆alkyl, R₃ is indanyl, and R₄ is H or C₁-C₆alkyl, classified in class 548 and subclass 356.1+.

Group VI, claim 138, X is O, R₁ is OH or C₁-C₆alkoxy, R₂ is H or C₁-C₆alkyl, R₃ is indanyl, and R₄ is H or C₁-C₆alkyl, drawn to a process for the preparation of a compound of the formula I, classified in class 548 and subclass 356.1+.

Group VII, claim 139, X is O, R₁ is OH or C₁-C₆alkoxy, R₂ is H or C₁-C₆alkyl, R₃ is (CH₂)_nQ wherein Q is thienyl, and R₄ is H or C₁-C₆alkyl, drawn to a compound of formula I, classified in class 548 and subclass 356.1+.

The Examiner has stated that this list is not exhaustive. The Examiner argues that "setting forth an exhaustive list is difficult under the time constraints due to the sheer volume of subject matter instantly claimed". The Examiner invited the Applicant to elect a single invention by identifying another specific embodiment not listed in the exemplary groups of the invention.

In response solely to be responsive to the requirement for restriction, Applicant provisionally elects, WITH TRAVERSAL, to prosecute claims to *another embodiment* not listed in the exemplary groups of the invention.

Applicant requests that the following Group be examined:

The Group encompassing claims 1, 2, 3, 6, 11, 16, 17, 18, 19, 20, 21, 124 and 125 drawn to compounds and compositions of formula I, wherein

X is N(CH₃) or O;

R₁ is OH or C₁₋₆ alkoxy;

R₂ is H or C₁₋₆ alkyl;

R₃ is (CH₂)_n Q, wherein

Q is thienyl, and

Q is optionally substituted with one or two moieties independently selected from halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, hydroxy, S(O)₂NH₂, trifluoromethyl, or cyano, and

n is 1 or 2; and